首页> 美国卫生研究院文献>PLoS Clinical Trials >Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model
【2h】

Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model

机译:使用人类胃癌衍生的85As2细胞在恶病质大鼠模型中生长素释放肽耐药性的发展以及Kampo药物rikkunshito对模型的姑息作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cancer cachexia (CC) is a multifactorial disease characterized by decreased food intake and loss of body weight due to reduced musculature with or without loss of fat mass. Patients with gastric cancer have a high incidence of cachexia. We previously established a novel CC rat model induced by human gastric cancer-derived 85As2 cells in order to examine the pathophysiology of CC and identify potential therapeutics. In patients with CC, anorexia is often observed, despite elevation of ghrelin, suggesting that ghrelin resistance may develop in these patients. In this study, we aimed to clarify the occurrence of ghrelin resistance in CC rats accompanied by anorexia and we investigated whether rikkunshito (RKT), a traditional Japanese Kampo medicine that potentiates ghrelin signaling, ameliorated CC-related anorexia through alleviation of ghrelin resistance. 85As2-tumor-bearing rats developed severe CC symptoms, including anorexia and loss of body weight/musculature, with the latter symptoms being greater in cachectic rats than in non-tumor-bearing or pair-fed rats. CC rats showed poor responses to intraperitoneal injection of ghrelin. In CC rats, plasma ghrelin levels were elevated and hypothalamic anorexigenic peptide mRNA levels were decreased, whereas hypothalamic growth hormone secretagogue receptor (GHS-R) mRNA was not affected. In vitro, RKT directly enhanced ghrelin-induced GHS-R activation. RKT administrated orally for 7 days partly alleviated the poor response to ghrelin and ameliorated anorexia without affecting the elevation of plasma ghrelin levels in CC rats. The expression of hypothalamic orexigenic neuropeptide Y mRNA but not hypothalamic GHS-R mRNA was increased by RKT. Thus, the 85As2 cell-induced CC rat model developed ghrelin resistance, possibly contributing to anorexia and body weight loss. The mechanism through which RKT ameliorated anorexia in the CC rat model may involve alleviation of ghrelin resistance by enhancement of ghrelin signaling. These findings suggest that RKT may be a promising agent for the treatment of CC.
机译:癌症恶病质(CC)是一种多因素疾病,其特征是由于肌肉组织的减少导致食物摄入减少和体重减轻,或没有或没有脂肪量减少。胃癌患者恶病质的发生率很高。我们先前建立了由人胃癌衍生的85As2细胞诱导的新型CC大鼠模型,以检查CC的病理生理并确定潜在的治疗方法。在CC患者中,尽管ghrelin升高,但仍经常观察到厌食症,这表明这些患者可能发生ghrelin耐药。在这项研究中,我们旨在弄清伴随厌食症的CC大鼠中ghrelin抵抗的发生,并且我们调查了可增强ghrelin信号传导的传统日本汉方药物rikkunshito(RKT)是否通过减轻ghrelin抵抗来缓解CC相关的厌食症。 85As2荷瘤大鼠出现严重的CC症状,包括厌食症和体重/肌肉组织丧失,恶病质大鼠的后者症状比非荷瘤或成对喂养的大鼠严重。 CC大鼠对腹膜内注射生长素释放肽显示不良反应。在CC大鼠中,血浆生长素释放肽水平升高,下丘脑厌食肽mRNA水平降低,而下丘脑生长激素促分泌素受体(GHS-R)mRNA不受影响。在体外,RKT直接增强了生长素释放肽诱导的GHS-R激活。口服给予RKT 7天可以部分缓解对生长激素释放肽的不良反应,改善厌食症,而不会影响CC大鼠血浆生长素释放肽的水平。 RKT增加下丘脑致病性神经肽Y mRNA的表达,但不增加下丘脑GHS-R mRNA的表达。因此,85As2细胞诱导的CC大鼠模型出现了生长素释放肽抵抗,可能导致厌食和体重减轻。 RKT改善CC大鼠模型中厌食的机制可能涉及通过增强Ghrelin信号传导来减轻Ghrelin抵抗。这些发现表明RKT可能是治疗CC的有前途的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号